Zerit licence restricted

HIV virus
HIV virus

Zerit (stavudine) is now indicated for use in patients with HIV infection only when other antiretrovirals cannot be used and then only for the shortest time possible with a switch to alternative therapy as soon as appropriate.

The SPC for the nucleoside reverse transcriptase inhibitor states that given the severe side effects associated with stavudine therapy, including lactic acidosis, lipoatrophy and polyneuropathy, a benefit-risk assessment should be conducted for each patient and use of an alternative antiretroviral carefully considered.

View Zerit drug record

Further information: Bristol-Myers Squibb

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases